Attached files
file | filename |
---|---|
EX-10.5 - EX-10.5 - TREVENA INC | trvn-20200331ex1051415a7.htm |
EX-32.2 - EX-32.2 - TREVENA INC | trvn-20200331ex32203ac9d.htm |
EX-32.1 - EX-32.1 - TREVENA INC | trvn-20200331ex3217abdee.htm |
EX-31.2 - EX-31.2 - TREVENA INC | trvn-20200331ex31205ca6a.htm |
EX-31.1 - EX-31.1 - TREVENA INC | trvn-20200331ex311e69c76.htm |
EX-10.4 - EX-10.4 - TREVENA INC | trvn-20200331ex104b23754.htm |
EX-10.3 - EX-10.3 - TREVENA INC | trvn-20200331ex103a11b6f.htm |
EX-10.2 - EX-10.2 - TREVENA INC | trvn-20200331ex102edefa7.htm |
EX-10.1 - EX-10.1 - TREVENA INC | trvn-20200331ex1012da6cb.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
Or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 001-36193
Trevena, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
26-1469215 |
|
|
955 Chesterbrook Boulevard, Suite 110 |
19087 |
Registrant’s telephone number, including area code: (610) 354-8840
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value |
TRVN |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:
Large accelerated filer ☐ |
Accelerated filer ☒ |
Non-accelerated filer ☐ |
Smaller reporting company ☒ |
Emerging growth company ☐ |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date.
Common Stock, $0.001 par value |
Shares outstanding as of May 5, 2020: 107,180,976 |
|
Page |
|
iii |
||
|
|
|
|
|
|
1 | ||
|
1 | |
|
2 | |
|
3 | |
|
4 | |
|
5 | |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
21 | |
30 | ||
30 | ||
|
|
|
31 | ||
31 | ||
32 | ||
33 | ||
33 | ||
33 | ||
33 | ||
|
|
|
35 |
ii
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10‑Q, or this “Quarterly Report,” contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but also are contained elsewhere in this Quarterly Report, as well as in sections such as “Risk Factors” that are incorporated by reference into this Quarterly Report from our most recent Annual Report on Form 10‑K, or the “Annual Report.” In particular, we caution you that our forward-looking statements are subject to the ongoing and developing circumstances related to the COVID-19 pandemic, which may have a material adverse effect on our business, operations and future financial results. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:
· |
any ongoing or planned clinical trials and preclinical studies for our product candidates; |
· |
the extent of future clinical trials potentially required by the FDA for our product candidates; |
· |
our ability to fund future operating expenses and capital expenditures with our current cash resources or to secure additional funding in the future; |
· |
the timing and likelihood of obtaining and maintaining regulatory approvals for our product candidates; |
· |
our plans to develop and potentially commercialize our product candidates; |
· |
the clinical utility and market acceptance of our product candidates, particularly in light of existing and future competition; |
· |
our sales, marketing, and manufacturing capabilities and strategies; |
· |
our intellectual property position; |
· |
ongoing litigation; and |
· |
our ability to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives. |
You should refer to the “Risk Factors” section of this Quarterly Report and our Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
iii
TREVENA, INC.
(in thousands, except share and per share data)
|
|
March 31, 2020 |
|
December 31, 2019 |
||
|
|
|
(unaudited) |
|
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
28,090 |
|
$ |
32,305 |
Marketable securities |
|
|
— |
|
|
3,500 |
Prepaid expenses and other current assets |
|
|
1,666 |
|
|
1,683 |
Total current assets |
|
|
29,756 |
|
|
37,488 |
Restricted cash |
|
|
1,310 |
|
|
1,309 |
Property and equipment, net |
|
|
2,577 |
|
|
2,705 |
Right-of-use lease asset |
|
|
5,389 |
|
|
5,472 |
Other assets |
|
|
18 |
|
|
20 |
Total assets |
|
$ |
39,050 |
|
$ |
46,994 |
Liabilities and stockholders’ equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable, net |
|
$ |
698 |
|
$ |
1,047 |
Accrued expenses and other current liabilities |
|
|
1,277 |
|
|
2,403 |
Current portion of loans payable, net |
|
|
— |
|
|
5,037 |
Lease liability |
|
|
642 |
|
|
620 |
Total current liabilities |
|
|
2,617 |
|
|
9,107 |
Leases, net of current portion |
|
|
7,636 |
|
|
7,804 |
Warrant liability |
|
|
2 |
|
|
5 |
Total liabilities |
|
|
10,255 |
|
|
16,916 |
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Common stock—$0.001 par value; 200,000,000 shares authorized at March 31, 2020 and December 31, 2019; 99,030,004 and 94,213,760 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively |
|
|
99 |
|
|
94 |
Preferred stock—$0.001 par value; 5,000,000 shares authorized, none issued or outstanding at March 31, 2020 and December 31, 2019 |
|
|
— |
|
|
— |
Additional paid-in capital |
|
|
447,566 |
|
|
443,129 |
Accumulated deficit |
|
|
(418,870) |
|
|
(413,145) |
Total stockholders’ equity |
|
|
28,795 |
|
|
30,078 |
Total liabilities and stockholders’ equity |
|
$ |
39,050 |
|
$ |
46,994 |
See accompanying notes to financial statements.
1
TREVENA, INC.
Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)
|
|
Three Months Ended |
||||
|
|
March 31, |
||||
|
|
2020 |
|
2019 |
||
Revenue: |
|
|
|
|
|
|
License revenue |
|
$ |
— |
|
$ |
— |
Operating expenses: |
|
|
|
|
|
|
General and administrative |
|
|
3,632 |
|
|
3,060 |
Research and development |
|
|
2,191 |
|
|
2,154 |
Total operating expenses |
|
|
5,823 |
|
|
5,214 |
Loss from operations |
|
|
(5,823) |
|
|
(5,214) |
Other income (expense): |
|
|
|
|
|
|
Change in fair value of warrant liability |
|
|
3 |
|
|
(12) |
Other income, net |
|
|
69 |
|
|
257 |
Interest income |
|
|
52 |
|
|
153 |
Interest expense |
|
|
(29) |
|
|
(353) |
Gain on foreign currency exchange |
|
|
3 |
|
|
— |
Total other income |
|
|
98 |
|
|
45 |
Loss before income tax expense |
|
|
(5,725) |
|
|
(5,169) |
Income tax expense |
|
|
— |
|
|
— |
Net loss attributable to common stockholders |
|
$ |
(5,725) |
|
$ |
(5,169) |
Other comprehensive gain, net: |
|
|
|
|
|
|
Unrealized gain on marketable securities |
|
|
— |
|
|
12 |
Other comprehensive gain, net |
|
|
— |
|
|
12 |
Comprehensive loss |
|
$ |
(5,725) |
|
$ |
(5,157) |
Per share information: |
|
|
|
|
|
|
Net loss per share of common stock, basic and diluted |
|
$ |
(0.06) |
|
$ |
(0.06) |
Weighted average common shares outstanding, basic and diluted |
|
|
96,332,324 |
|
|
88,897,292 |
See accompanying notes to financial statements.
2
TREVENA, INC.
Statement of Stockholders’ Equity (Unaudited)
(in thousands, except share data)
|
|
Stockholders' Equity |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
Other |
|
|
|
||||
|
|
Number |
|
$0.001 |
|
Additional |
|
|
|
|
Comprehensive |
|
Total |
||||
|
|
of |
|
Par |
|
Paid-in |
|
Accumulated |
|
Income |
|
Stockholders' |
|||||
|
|
Shares |
|
Value |
|
Capital |
|
Deficit |
|
(Loss) |
|
Equity |
|||||
Balance, January 1, 2020 |
|
94,213,760 |
|
$ |
94 |
|
$ |
443,129 |
|
$ |
(413,145) |
|
$ |
— |
|
$ |
30,078 |
Stock-based compensation expense |
|
— |
|
|
— |
|
|
891 |
|
|
— |
|
|
— |
|
|
891 |
Issuance of common stock, net of issuance costs |
|
4,816,244 |
|
|
5 |
|
|
3,546 |
|
|
— |
|
|
— |
|
|
3,551 |
Net loss |
|
— |
|
|
— |
|
|
— |
|
|
(5,725) |
|
|
|
|
|
(5,725) |
Balance, March 31, 2020 |
|
99,030,004 |
|
$ |
99 |
|
$ |
447,566 |
|
$ |
(418,870) |
|
$ |
— |
|
$ |
28,795 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, January 1, 2019 |
|
82,323,413 |
|
$ |
82 |
|
$ |
429,727 |
|
$ |
(388,274) |
|
$ |
(9) |
|
$ |
41,526 |
Stock-based compensation expense |
|
— |
|
|
— |
|
|
754 |
|
|
— |
|
|
— |
|
|
754 |
Exercise of stock options |
|
30,225 |
|
|
— |
|
|
21 |
|
|
— |
|
|
— |
|
|
21 |
Issuance of warrants to underwriters in connection with equity offering |
|
— |
|
|
— |
|
|
347 |
|
|
— |
|
|
— |
|
|
347 |
Issuance of common stock, net of issuance costs |
|
10,000,000 |
|
|
10 |
|
|
8,886 |
|
|
— |
|
|
— |
|
|
8,896 |
Unrealized gain on marketable securities |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
12 |
|
|
12 |
Net loss |
|
— |
|
|
— |
|
|
— |
|
|
(5,169) |
|
|
— |
|
|
(5,169) |
Balance, March 31, 2019 |
|
92,353,638 |
|
$ |
92 |
|
$ |
439,735 |
|
$ |
(393,443) |
|
$ |
3 |
|
$ |
46,387 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to financial statements.
3
TREVENA, INC.
Statements of Cash Flows (Unaudited)
(in thousands)
|
|
Three Months Ended |
||||
|
|
March 31, |
||||
|
|
2020 |
|
2019 |
||
Operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(5,725) |
|
$ |
(5,169) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
|
128 |
|
|
149 |
Stock-based compensation |
|
|
891 |
|
|
754 |
Noncash interest expense on loans |
|
|
8 |
|
|
123 |
Revaluation of warrant liability |
|
|
(3) |
|
|
12 |
(Accretion) amortization of bond (discount) premium on marketable securities |
|
|
— |
|
|
(159) |
Change in right-of-use asset |
|
|
83 |
|
|
— |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Prepaid expenses and other assets |
|
|
19 |
|
|
(974) |
Operating lease liabilities |
|
|
(144) |
|
|
— |
Accounts payable, accrued expenses and other liabilities |
|
|
(1,475) |
|
|
(2,419) |
Net cash used in operating activities |
|
|
(6,218) |
|
|
(7,683) |
Investing activities: |
|
|
|
|
|
|
Maturities of marketable securities |
|
|
3,500 |
|
|
18,179 |
Purchases of marketable securities |
|
|
— |
|
|
(29,219) |
Net cash (used in) provided by investing activities |
|
|
3,500 |
|
|
(11,040) |
Financing activities: |
|
|
|
|
|
|
Proceeds from exercise of common stock options |
|
|
— |
|
|
21 |
Proceeds from issuance of common stock, net |
|
|
3,551 |
|
|
9,243 |
Capital lease payments |
|
|
(2) |
|
|
(3) |
Repayments of loans payable, net |
|
|
(5,045) |
|
|
(3,167) |
Net cash (used in) provided by financing activities |
|
|
(1,496) |
|
|
6,094 |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(4,214) |
|
|
(12,629) |
Cash, cash equivalents and restricted cash—beginning of period |
|
|
33,614 |
|
|
34,195 |
Cash, cash equivalents and restricted cash—end of period |
|
$ |
29,400 |
|
$ |
21,566 |
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
Cash paid for interest |
|
$ |
18 |
|
$ |
229 |
Fair value of common stock warrants issued to underwriters |
|
$ |
347 |
|
$ |
347 |
See accompanying notes to financial statements.
4
TREVENA, INC.
Notes to Unaudited Financial Statements
March 31, 2020
1. Organization and Description of the Business
Trevena, Inc., or the Company, was incorporated in Delaware as Parallax Therapeutics, Inc. on November 9, 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. on January 3, 2008. The Company is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system, or CNS, disorders. The Company operates in one segment and has its principal office in Chesterbrook, Pennsylvania.
Since commencing operations in 2007, the Company has devoted substantially all of its financial resources and efforts to research and development, including nonclinical studies and clinical trials. The Company has never been profitable and has not yet commenced commercial operations. In November 2018, the U.S. Food and Drug Administration, or FDA, issued a complete response letter, or CRL, with respect to the Company’s new drug application, or NDA, for oliceridine. In the CRL, the FDA requested additional clinical data on the QT interval and indicated that the submitted safety database was not of adequate size for the proposed labeling. The FDA also requested certain additional nonclinical data and validation reports. In January 2019, the Company announced the receipt of the official Type A meeting minutes from the FDA regarding the CRL wherein it agreed that the current oliceridine safety database will support labeling at a maximum daily dose of 27 mg. The FDA also agreed that the Company can conduct a study in healthy volunteers to collect the requested QT interval data and that the study should include placebo- and positive-control arms. The Company initiated the healthy volunteer QT study in June 2019 following its receipt of feedback from the FDA on key design elements for the study and analysis plan. In August 2019, the Company announced that it had completed enrollment in the healthy volunteer QT study, completed the nonclinical work to characterize the 9662 metabolite, and completed the remaining product validation reports requested by the FDA. In November 2019, the Company reported topline data from the healthy volunteer QT study. In February 2020, the Company resubmitted the oliceridine NDA and in March 2020, the FDA set a PDUFA goal date of August 7, 2020 for the completion of its review of the NDA.
Since its inception, the Company has incurred losses and negative cash flows from operations. At March 31, 2020, the Company had an accumulated deficit of $418.9 million. The Company’s net loss was $5.7 million and $5.2 million for the three months ended March 31, 2020 and 2019, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements—Going Concern, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The Company’s existing balance of cash and cash equivalents as of March 31, 2020 is not sufficient to fund operations for one year after the date the financial statements are issued. While there is substantial doubt about the Company’s ability to continue as a going concern through the year period from the date of this filing, management’s plans to mitigate this risk include raising additional capital through equity or debt financings, or through strategic transactions. Management’s plans may also include the possible deferral of certain operating expenses unless and until additional capital is received. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses, or that the COVID-19 pandemic will not have an impact on the Company’s ability to raise capital or fund its operations as planned. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the ASC and Accounting Standards Update, or ASU, of FASB. The Company’s functional currency is the U.S. dollar.
5
The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s balance sheets as of March 31, 2020 and December 31, 2019, its results of operations and its comprehensive loss for the three months ended March 31, 2020 and 2019, its statement of stockholders’ equity for the period from January 1, 2020 to March 31, 2020 and for the period January 1, 2019 to March 31, 2019, and its statements of cash flows for the three months ended March 31, 2020 and 2019. The information included in this Quarterly Report on Form 10‑Q should be read in conjunction with the financial statements and accompanying notes included in the Company’s most recent Annual Report on Form 10‑K for the year ended December 31, 2019. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. The financial data and other information disclosed in these notes related to the three months ended March 31, 2020 and 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period.
We have been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. The financial results for the three months ended March 31, 2020, were not significantly impacted by COVID-19. Remote working arrangements and travel restrictions imposed by various jurisdictions have had limited impact on our ability to maintain operations during the quarter. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience as well as other pertinent industry and regulatory authority information, including the potential future effects of COVID-19, the results of which form the basis for making judgements about the carrying values of assets and liabilities and the recording expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Fair Value of Financial Instruments
The carrying amount of the Company’s financial instruments, which include cash and cash equivalents, marketable securities, restricted cash, accounts payable and accrued expenses approximate their fair values, given their short-term nature. The carrying amount of the Company’s loans payable at December 31, 2019 was the nominal value of the loan payable, net of debt discount and deferred charges. The nominal value approximated fair value because the interest rate was reflective of the rate the Company could obtain on debt similar terms and conditions. Certain of the Company’s common stock warrants are carried at fair value, as disclosed in Note 3.
Leases
The Company adopted ASU 2016‑02, Leases (Topic 842), and all applicable amendments as of January 1, 2019 using a modified retrospective approach. The Company determines if an arrangement is a lease at inception. Operating leases are included in long-term right-of-use assets and current and long-term lease liabilities on our consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The right-of-use assets are tested for impairment according to ASC 360. See Note 6 for details. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these immaterial leases on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component under the practical expedient provisions of the standard. Lease payments, which may include lease and
6
non-lease components, are included in the measurement of the Company’s lease liabilities to the extent that such payments are either fixed amounts or variable amounts that depend on a rate or index as stipulated in the lease contract.
Revenue
In accordance with FASB’s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps:
(i) |
identify the contract(s) with a customer; |
(ii) |
identify the performance obligations in the contract; |
(iii) |
determine the transaction price; |
(iv) |
allocate the transaction price to the performance obligations in the contract; and |
(v) |
recognize revenue when (or as) the entity satisfies a performance obligation. |
The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as Current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as Deferred revenue, net of current portion.
License Revenues
The Company’s revenues have primarily been generated through licensing arrangements. The terms of these agreements typically include payment to the Company of one or more of the following: nonrefundable, up-front license fees; regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. See Note 7.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps:
(i) |
identification of the promised goods or services in the contract; |
(ii) |
determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; |
(iii) |
measurement of the transaction price, including the constraint on variable consideration; |
(iv) |
allocation of the transaction price to the performance obligations; and |
(v) |
recognition of revenue when (or as) the Company satisfies each performance obligation. |
The Company also assesses whether there is an option in a contract to acquire additional goods or services. An option gives rise to a performance obligation only if the option provides a material right to the customer that it would not
7
receive without entering into that contract. Factors that the Company considers in evaluating whether an option represents a material right include, but are not limited to: (i) the overall objective of the arrangement, (ii) the benefit the collaborator might obtain from the arrangement without exercising the option, (iii) the cost to exercise the option (e.g. priced at a significant and incremental discount), and (iv) the likelihood that the option will be exercised. With respect to options determined to be performance obligations, the Company recognizes revenue when those future goods or services are transferred or when the options expire.
The Company’s revenue arrangements may include the following:
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments: At the inception of an agreement that includes regulatory or commercial milestone payments, the Company evaluates whether each milestone is considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At each reporting period, the Company assesses the probability of achievement of each milestone under its current agreements.
Research and Development Activities: Under the Company’s current collaboration and license arrangements, if the Company is entitled to reimbursement for costs for services provided by the Company, it expects such reimbursement would be an offset to research and development expenses.
Royalties: If the Company is entitled to receive sales-based royalties from its collaborator, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, provided the reported sales are reliably measurable, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Manufacturing Supply and Research Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
The Company receives payments from its licensees based on schedules established in each contract. Upfront payments are recorded as deferred revenue upon receipt, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.
Income Taxes
Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, or ASC 740, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
8
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. To date, the Company has not taken any uncertain tax position or recorded any reserves, interest or penalties.
On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act makes the following changes to the U.S. tax code that will affect 2018, 2019 and 2020, including, but not limited to, (1) temporary modification of the adjusted taxable income limitation under Section 163(j) from 30% to 50% for tax years 2019 and 2020 only; (2) modification to the net operating loss rules surrounding the ability to now carryback five years net operating losses generated in 2018, 2019, and 2020; (3) temporary repeal of the net operating loss taxable income limitation of 80%; and (4) temporary enhancement of corporate charitable contribution limitation to 25% of taxable income for tax year 2020 only. There no impact to Q1 2020 tax provision for these tax law changes.
Recently Adopted Accounting Standards
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance modifies the disclosure requirements related to fair value measurements in Topic 820, Fair Value Measurement, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and modifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The effective date for both standards in January 1, 2020. The Company adopted these standards on January 1, 2020. There was no impact to the Company’s financial statements upon the adoption.
Recent Accounting Standards Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, which removed certain exceptions to the general principles of the accounting for income taxes and also improves consistent application of and simplification of other areas when accounting for income taxes. The guidance is effective for the Company beginning in the first quarter of fiscal year 2021. Early adoption is permitted. The Company is evaluating the effect this standard will have on its financial statements and related disclosures.
3. Fair Value of Financial Instruments
ASC 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.
ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
· |
Level 1‑Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. |
· |
Level 2‑Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. |
· |
Level 3‑Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
9
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Cash, Cash Equivalents and Marketable Securities
The following table presents fair value of the Company’s cash, cash equivalents, and marketable securities as of March 31, 2020 and December 31, 2019 (in thousands):
March 31, 2020 |
|||||||||||||||||||||
Adjusted |
Unrealized |
Unrealized |
Cash and Cash |
Restricted |
Marketable |
||||||||||||||||
Cost |
Gains |
Losses |
Fair Value |
Equivalents |
Cash |
Securities |
|||||||||||||||
Cash |
|
$ |
8,980 |
|
$ |
— |
|
$ |
— |
|
$ |
8,980 |
|
$ |
7,670 |
|
$ |
1,310 |
|
$ |
— |
Level 1 (1): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
|
17,420 |
|
|
— |
|
|
— |
|
|
17,420 |
|
|
17,420 |
|
|
— |
|
|
— |
U.S. treasury securities |
|
|
3,000 |
|
|
— |
|
|
— |
|
|
3,000 |
|
|
3,000 |
|
|
— |
|
|
|
Subtotal |
|
|
20,420 |
|
|
— |
|
|
— |
|
|
20,420 |
|
|
20,420 |
|
|
— |
|
|
— |
Level 2 (2): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government agency securities |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
— |
Total |
|
$ |
29,400 |
|
$ |
— |
|
$ |
— |
|
$ |
29,400 |
|
$ |
28,090 |
|
$ |
1,310 |
|
$ |
— |
|
|
December 31, 2019 |
|||||||||||||||||||
|
|
Adjusted |
|
Unrealized |
|
Unrealized |
|
|
|
|
Cash and Cash |
|
Restricted |
|
Marketable |
||||||
|
|
Cost |
|
Gains |
|
Losses |
|
Fair Value |
|
Equivalents |
|
Cash |
|
Securities |
|||||||
Cash |
|
$ |
9,302 |
|
$ |
— |
|
$ |
— |
|
$ |
9,302 |
|
$ |
7,993 |
|
$ |
1,309 |
|
$ |
— |
Level 1 (1): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
|
18,306 |
|
|
— |
|
|
— |
|
|
18,306 |
|
|
18,306 |
|
|
— |
|
|
— |
U.S. treasury securities |
|
|
5,996 |
|
|
— |
|
|
— |
|
|
5,996 |
|
|
2,496 |
|
|
— |
|
|
3,500 |
Subtotal |
|
|
24,302 |
|
|
— |
|
|
— |
|
|
24,302 |
|
|
20,802 |
|
|
— |
|
|
3,500 |
Level 2 (2): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government agency securities |
|
|
3,510 |
|
|
— |
|
|
— |
|
|
3,510 |
|
|
3,510 |
|
|
— |
|
|
— |
Total |
|
$ |
37,114 |
|
$ |
— |
|
$ |
— |
|
$ |
37,114 |
|
$ |
32,305 |
|
$ |
1,309 |
|
$ |
3,500 |
(1) |
The fair value of Level 1 securities is estimated based on quoted prices in active markets for identical assets or liabilities. |
(2) |
The fair value of Level 2 securities is estimated based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
The Company classifies investments available to fund current operations as current assets on its balance sheets. As of March 31, 2020, the Company did not hold any investment securities exceeding a one-year maturity.
The Company maintains $1.3 million as collateral under a letter of credit for the Company’s facility lease obligations in Chesterbrook, Pennsylvania. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its balance sheet.
Unrealized gains and losses on marketable securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity. Realized gains (losses) are included in interest income (expense) in the statement of operations and comprehensive income (loss) on a specific identification basis. The Company did not record any realized gains or losses during the three months ended March 31, 2020 and 2019. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
10
Accretion of bond discount on marketable securities is included in other income as a separate component of other income (expense) on the statement of operations and comprehensive loss. Interest income on marketable securities is recorded as interest income on the statement of operations and comprehensive loss.
The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 2 and Level 3 during the three months ended March 31, 2020 or the year ended December 31, 2019.
4. Loans Payable
In September 2014, the Company entered into a loan and security agreement with Oxford Finance LLC and Pacific Western Bank (formerly Square 1Bank) (together, the lenders), pursuant to which the lenders agreed to lend the Company up to $35.0 million in a three-tranche series of term loans (Term Loans A, B, and C). We were required to make payments of interest only on borrowings under the loan agreement on a monthly basis through and including January 1, 2018; payments of principal in equal monthly installments and accrued interest began on January 1, 2018 and continued until the loan matured on March 1, 2020. On March 2, 2020, we made our final payment under the loan and security agreement with Oxford Finance LLC and Pacific Western Bank. Upon the last payment date of the amounts borrowed under the agreement, we were required to pay a final payment fee of $1.9 million, equal to 6.6% of the aggregate amounts borrowed.
In connection with entering into the agreement, the Company issued to the lenders and the placement agent warrants to purchase an aggregate of 7,678 shares of Trevena’s common stock, of which 5,728 shares remain outstanding as of March 31, 2020. These detachable warrant instruments have qualified for equity classification and have been allocated upon the relative fair value of the base instrument and the warrants, according to the guidance of ASC 470-20-25-2. These warrants are exercisable immediately and have an exercise price of $5.8610 per share. The warrants may be exercised on a cashless basis and will terminate on the earlier of September 19, 2024 or the closing of a merger or consolidation transaction in which the Company is not the surviving entity. In connection with the draw of Term Loan B, the Company issued to the lenders and the placement agent additional warrants to purchase an aggregate of 34,961 shares of Trevena common stock. These warrants have substantially the same terms as those noted above, have an exercise price of $10.6190 per share and an expiration date of December 23, 2025. In connection with draw of Term Loan C, the Company issued to the lenders and placement agent additional warrants to purchase an aggregate of 62,241 shares of the Company’s common stock. These warrants have substantially the same terms as those noted above and have an exercise price of $3.6150 per share and an expiration date of March 31, 2027. These detachable warrant instruments have qualified for equity classification and have been allocated upon the relative fair value of the base instrument and the warrants, according to the guidance of ASC 470-20-25-2.
As of March 31, 2020, principal borrowings of $3.2 million attributable to Term Loans A, B, and C, including a final payment fee of $1.9 million, are fully paid off. Interest expense of $0.02 million and $0.2 million was recorded during the three months ended March 31, 2020 and 2019, respectively. The Company incurred lender and third-party costs of $1.0 million related to the issuance of its term loans. Per ASU 2015‑03, Interest-Imputation of Interest, debt discount and debt issuance costs are to be presented as a contra-liability to the debt on the balance sheet. These costs were amortized to interest expense over the life of the loans using the effective interest method. Immaterial amounts of debt discount and debt issuance cost were amortized to interest expense during the three months ended March 31, 2020 and 2019, respectively.
The following table summarizes how the issuance of Term Loans A, B, and C are reflected on the balance sheet at March 31, 2020 and December 31, 2019 (in thousands):
|
|
March 31, |
|
December 31, |
|
||
|
|
2020 |
|
2019 |
|
||
Gross proceeds |
|
$ |
— |
|
$ |
3,167 |
|
Debt discount and debt issuance costs (1) |
|
|
— |
|
|
1,870 |
|
Carrying value |
|
|
— |
|
|
5,037 |
|
Current portion of loans payable, net |
|
|
— |
|
|
5,037 |
|
Loans payable, net |
|
$ |
— |
|
$ |
— |
|
(1) |
Includes the final fee payment due upon last payment date of the amounts borrowed. |
11
5. Stockholders’ Equity
Equity Offerings
ATM Programs
Under its certificate of incorporation, the Company was authorized to issue up to 200,000,000 shares of common stock as of March 31, 2020. The Company also was authorized to issue up to 5,000,000 shares of preferred stock as of March 31, 2020. The Company is required, at all times, to reserve and keep available out of its authorized but unissued shares of common stock sufficient shares to effect the conversion of the shares of the preferred stock and all outstanding stock options and warrants.
On April 17, 2019, the Company entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC, or Wainwright, pursuant to which the Company may offer and sell through Wainwright, from time to time at the Company’s sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the ATM Program. Sales of the shares of common stock are deemed to be “at the market offerings,” as defined in Rule 415 under the Securities Act. The Company intends to use the net proceeds from the offering primarily for the development of its lead product candidate, oliceridine, and for general corporate purposes. In the first quarter of 2020, the Company issued and sold approximately 4.8 million shares of common stock under the ATM Program. The net offering proceeds for sales under the ATM Program were approximately $3.6 million after deducting related expenses, including commissions. As of March 31, 2020, there was $45.2 million remaining available for future issuances under the ATM Program.
Registered Direct Offering and Concurrent Warrant Issuance
On January 29, 2019, the Company entered into securities purchase agreements with two institutional investors wherein the Company agreed to sell to the investors an aggregate of 10,000,000 shares of its common stock, at an offering price of $1.00 per share, in a registered direct offering made pursuant to the Company’s existing registration statement on Form S-3. The net proceeds to the Company from the offering were approximately $9.2 million, after deducting fees and the expenses of the placement agent. Pursuant to a letter agreement dated January 28, 2019, the Company engaged H.C. Wainwright & Co., LLC, or Wainwright, to act as its exclusive placement agent in connection with the issuance and sale of the shares. The Company paid Wainwright 7.0% of the aggregate gross proceeds in the offering and $50,000 for certain expenses, and it issued warrants to purchase 500,000 shares of common stock to certain designees of Wainwright. These warrants have a term of five years, are immediately exercisable and have an exercise price of $1.25 per share. The warrants are classified as equity and recorded at fair value as of the date of issuance on the Company’s Consolidated Balance Sheets and no further adjustments to their valuation are made. The letter agreement also includes indemnification obligations of the Company and other provisions customary for transactions of this nature.
Equity Incentive Plans
In 2008, the Company adopted the 2008 Equity Incentive Plan, as amended on February 29, 2008, January 7, 2010, July 8, 2010, December 10, 2010, June 23, 2011 and June 17, 2013, collectively, the 2008 Plan, that authorized the Company to grant restricted stock and stock options to eligible employees, directors and consultants to the Company.
In 2013, the Company adopted the 2013 Equity Incentive Plan, as amended on May 14, 2014, collectively, 2013 Plan. The 2013 Plan became effective upon the Company’s entry into the underwriting agreement related to its IPO in January 2014 and, as of such date, no further grants were permitted under the 2008 Plan. The 2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company. Additionally, the 2013 Plan provides for the grant of cash and stock-based performance awards. The 2013 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock available for issuance under the plan automatically increases on January 1 of each year beginning in 2015.
On December 15, 2016, the Company adopted the Trevena, Inc. Inducement Plan, or the Inducement Plan, effective January 1, 2017, pursuant to which the Company reserved 500,000 shares of the Company’s common stock for issuance under the Inducement Plan. The Plan provides for nonstatutory stock options and restricted stock unit awards.
12
The only persons eligible to receive grants of awards under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635‑1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company.
Under all of such plans, the amount, terms of grants and exercisability provisions are determined by the board of directors or its designee. The term of the options may be up to 10 years, and options are exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than four years. For performance-based stock awards, the Company recognizes expense when achievement of the performance factor is probable, over the requisite service period.
The estimated grant-date fair value of the Company’s stock-based awards is amortized on a straight-line basis over the awards’ service periods. Stock-based compensation expense recognized was as follows (in thousands):
|
|
Three Months Ended March 31, |
|
||||
|
|
2020 |
|
2019 |
|
||
Research and development |
|
$ |
209 |
|
$ |
232 |
|
General and administrative |
|
|
682 |
|
|
522 |
|
Total stock-based compensation |
|
$ |
891 |
|
$ |
754 |
|
Stock Options
A summary of stock option activity and related information through March 31, 2020 follows:
|
|
Options Outstanding |
|||||
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Average |
|
|
|
|
Weighted |
|
Remaining |
|
|
|
|
|
Average |
|
Contractual |
|
|
|
Number of |
|
Exercise |
|
Term |
|
|
|
Shares |
|
Price |
|
(in years) |
|
Balance, December 31, 2019 |
|
7,568,304 |
|
$ |
3.40 |
|
7.01 |
Granted |
|
230,000 |
|
|
0.80 |
|
|
Exercised |
|
— |
|
|
— |
|
|
Forfeited/Cancelled |
|
(207,874) |
|
|
(3.69) |
|
|
Balance, March 31, 2020 |
|
7,590,430 |
|
$ |
3.32 |
|
6.94 |
Vested or expected to vest at March 31, 2020 |
|
7,590,430 |
|
$ |
3.32 |
|
6.94 |
Exercisable at March 31, 2020 |
|
4,812,040 |
|
$ |
4.23 |
|
6.03 |
The intrinsic value of the options exercisable as of March 31, 2020 was $0 because none of the exercisable options had an exercise price that was below the Company’s closing stock price at March 31, 2020 of $0.57 per share. At March 31, 2020, there was $2.4 million of total unrecognized compensation expense related to unvested options that will be recognized over the weighted average remaining vesting period of 2.03 years.
The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes model requires the Company to make certain estimates and assumptions, including estimating the fair value of the Company’s common stock, assumptions related to the expected price volatility of the Company’s common stock, the period during which the options will be outstanding, the rate of return on risk-free investments and the expected dividend yield for the Company’s common stock.
The per-share weighted-average grant date fair value of the options granted to employees and directors during the three months ended March 31, 2020 and 2019 was estimated at $0.62 and $1.04 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
13
|
|
March 31, |
|
|
||
|
|
2020 |
|
2019 |
|
|
Expected term of options (in years) |
|
6.3 |
|
6.3 |
|
|
Risk-free interest rate |
|
1.5 |
% |
2.5 |
% |
|
Expected volatility |
|
95.4 |
% |
75.4 |
% |
|
Dividend yield |
|
— |
% |
— |
% |
|
Restricted Stock Units
On December 5, 2019, the Company granted 2,170,585 restricted stock units, or RSUs, to employees. The units vest subject to the satisfaction of service requirements as follows: 50% vest on December 5, 2020, and 50% vest on December 5, 2021. The fair market value per RSU is $0.72, which is equal to the closing price of the Company’s common stock on the date of the grant.
On December 6, 2018, the Company granted 1,255,000 RSUs to employees. The units vest subject to the satisfaction of service requirements as follows: 25% vested on June 1, 2019, 25% vest on December 1, 2019, and the remaining vest on December 6, 2020. The closing price of the Company’s common stock on the date of the grant was $0.64 per share, which is the fair market value per unit of the RSUs.
RSU-related expense is recognized on a straight-line basis over the vesting period. Upon vesting, these awards may be settled on a net-exercise basis to cover any required withholding tax with the remaining amount converted into an equivalent number of shares of common stock.
The following is a summary of changes in the status of non-vested RSUs during the year:
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
Average |
|
|
|
Number of |
|
Grant Date |
|
|
|
Awards |
|
Fair Value |
|
Non-vested at December 31, 2019 |
|
2,945,585 |
|
$ |
0.73 |
Granted |
|
250,000 |
|
|
0.79 |
Vested |
|
— |
|
|
— |
Forfeited |
|
(118,400) |
|
|
0.70 |
Non-vested at March 31, 2020 |
|
3,077,185 |
|
$ |
0.73 |
For the three months ended March 31, 2020, the Company recorded $0.3 million in stock-based compensation expense related to RSUs, which is reflected in the statement of operations.
As of March 31, 2020, there was $1.9 million of total unrecognized compensation expense related to unvested RSUs that will be recognized over the weighted average remaining period of 1.98 years.
Shares Available for Future Grant
At March 31, 2020, the Company has the following shares available to be granted under its equity incentive plans:
|
|
|
|
Inducement |
|
|
2013 Plan |
|
Plan |
Available at December 31, 2019 |
|
4,394,301 |
|
205,000 |
Authorized |
|
3,768,550 |
|
— |
Granted |
|
(480,000) |
|
— |
Forfeited/Cancelled |
|
302,524 |
|
23,750 |
Available at March 31, 2020 |
|
7,985,375 |
|
228,750 |
14
Shares Reserved for Future Issuance
At March 31, 2020, the Company has reserved the following shares of common stock for issuance:
Stock options outstanding under 2013 Plan |
|
7,319,180 |
Restricted stock units outstanding under 2013 Plan |
|
3,077,185 |
Shares reserved for future issuance under 2013 Plan |
|
7,985,375 |
Stock options outstanding under Inducement Plan |
|
271,250 |
Shares reserved for future issuance under Inducement Plan |
|
228,750 |
Shares reserved for future issuance under 2013 Employee Stock Purchase Plan |
|
225,806 |
Warrants outstanding |
|
623,091 |
Total shares of common stock reserved for future issuance |
|
19,730,637 |
6. Commitments and Contingencies
Leases
The Company leases office space in Chesterbrook, Pennsylvania and equipment. The Company’s principal office is located at 955 Chesterbrook Boulevard, Chesterbrook, Pennsylvania, where the Company currently leases approximately 8,231 square feet of developed office space on the first floor and 40,565 square feet of developed office space on the second floor. The lease term for this space extends through May 2028. On October 11, 2018, the Company entered into an agreement with The Vanguard Group, Inc., or Vanguard, whereby Vanguard agreed to sublease the 40,565 square feet of space on the second floor for an initial term of 37 months. Vanguard has an option to extend the sublease term for 3 years, and a second option to extend the sublease until November 30, 2027. The sublease provides for rent abatement for the first month of the term; thereafter, the rent payable to the Company by Vanguard under the sublease is (i) $0.50 less during months 2 through 13 of the sublease and (ii) in month 14 and thereafter of the sublease, $1.00 less than the base rent payable by the Company under its master lease with Chesterbrook Partners, L.P. Vanguard also is responsible for paying to the Company all tenant energy costs, annual operating costs, and annual tax costs attributable to the subleased space during the term of the sublease. Rent expense and associated sublease income are recorded in the Company’s statements of operations and comprehensive loss as other income (expense).
In October 2017, the Company terminated its lease related to vivarium space in Exton, Pennsylvania, under an agreement expiring on December 31, 2018. The Company incurred termination fees equivalent to three months’ rent, totaling less than $0.1 million, in relation to the early termination of this agreement. Additionally, in November 2017, the Company provided notice of its intent to terminate its facility lease of approximately 16,714 square feet of office and laboratory space in King of Prussia, Pennsylvania, under an agreement that expires in September 2020. The Company paid the landlord a $0.15 million termination fee on the date the Company exercised the termination option. This lease was deemed terminated on August 15, 2018.
15
Supplemental balance sheet information related to leases was as follows (in thousands):
|
|
March 31, 2020 |
|
December 31, 2019 |
|
||
Operating leases: |
|
|
|
|
|
|
|
Operating lease right-of-use assets |
|
$ |
5,389 |
|
$ |
5,472 |
|
Other current liabilities |
|
|
632 |
|
|
611 |
|
Operating lease liabilities |
|
|
7,627 |
|
|
7,793 |
|
Total operating lease liabilities |
|
$ |
8,259 |
|
$ |
8,404 |
|
|
|
|
|
|
|
|
|
Finance leases: |
|
|
|
|
|
|
|
Property and equipment, at cost |
|
$ |
45 |
|
$ |
45 |
|
Accumulated depreciation |
|
|
(27) |
|
|
(25) |
|
Property and equipment, net |
|
|
18 |
|
|
20 |
|
Other current liabilities |
|
|
9 |
|
|
9 |
|
Other long-term liabilities |
|
|
9 |
|
|
11 |
|
Total finance lease liabilities |
|
$ |
18 |
|
$ |
20 |
|
The components of lease expense were as follows (in thousands):
|
|
Three Months Ended |
||||
|
|
March 31, |
||||
|
|
|